Endogenous Cannabinoids in Crohn’s Disease DOI Creative Commons

Michał S. Bochenek,

J. Tomášík, Andrzej Wędrychowicz

et al.

Applied Sciences, Journal Year: 2024, Volume and Issue: 14(15), P. 6646 - 6646

Published: July 30, 2024

Background: An increasing number of people around the world suffer from Crohn’s disease (CD), one inflammatory bowel diseases (IBDs). Recent evidence suggests that endogenous cannabinoid system plays an important role in IBD. The main endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), are ligands CB1 CB2 receptors expressed on immune cells. These as well endocannabinoids believed to mediate activity participate pathophysiology CD. Objective: Very little is known about secretion cannabinoids throughout course Therefore, aim this study was determine analyze 2-AG AEA concentrations children who suffered Methods: We studied 34 adolescents with CD, mean age 13.5 years ± 2.0. Blood samples were collected three times active phase (during admission hospital, before treatment), 2–4 weeks later, during treatment clinical improvement patients, 3–6 months period remission. control group included 33 healthy teenagers same examined once. In all fasting blood morning. 2AG serum measured using EIA kits (Abclonal, Woburn, MA, USA ELK Biotechnology Co., Ltd. Wuhan, China, respectively). Results: median concentration stable: acute 907.4 [379.3; 1300.5] pg/mL, 715.1 [416.7; 1302.5] pg/mL; remission 991.1 [381.1; 1652.5] similar values observed 761.8 [504.3; 1497.0] pg/mL. No significant differences found between results obtained at time points compared (in cases p > 0.44). case AEA, treatment, 2.63 [2.24; 2.79] ng/mL 2.56 [2.33; 3.06] ng/mL, remission, 2.61 [2.46; 2.85] ng/mL. All these lower 3.18 [2.57; 3.88] (p = 0.023, 0.035, 0.056, Conclusions: While levels remained stable comparable controls, consistently CD patients. therapeutic interventions aimed AEA-related signaling, such administration its analogues or fatty acid amide hydrolase inhibitors, may improve symptoms associated children.

Language: Английский

Increasing trends of cannabinoid hyperemesis syndrome in youth: The grass is not always greener DOI Open Access
Benjamin Jack, Apryl Susi, Patrick T. Reeves

et al.

Journal of Pediatric Gastroenterology and Nutrition, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 27, 2025

Abstract This study investigated trends in suspected cannabinoid hyperemesis syndrome (CHS)‐related emergency department visits among youth (15–24 years old) the United States between 2006 and 2020. Using data from Nationwide Emergency Room Sample, over 55,000 CHS‐related were identified, with an average annual increase of 28.1% per year. aligns rising cannabis use potency across nation. Subjects western region, males, those public insurance more likely to present CHS. These findings highlight growing health concern CHS emphasize need for increased awareness healthcare providers, particularly regarding potential link chronic youth. Further research is needed understand underlying mechanisms risk factors associated as well impact policy on outcomes.

Language: Английский

Citations

1
Síndrome de hiperémesis cannabinoide: una revisión DOI Creative Commons
Raúl Alberto Jiménez‐Castillo, S. Arumugam, J.M. Remes-Troche

et al.

Revista de Gastroenterología de México, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Citations

0
Marijuana Use as a Lifestyle Factor Associated With Gastroesophageal Reflux Disease (GERD) Complications DOI

Adedeji O Adenusi,

Nisha Sapkota,

Abdelaziz Mohamed

et al.

American Journal of Lifestyle Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: June 6, 2025

Introduction: GERD is one of the most diagnosed digestive disorders globally, with an estimated 20% prevalence in US. Marijuana use US, and has shown a consistent uptrend. This study aims to detect any relationship between marijuana complications. Methods: We used National Inpatient Sample dataset for 2016-2020 this retrospective study. Our outcomes were reflux esophagitis Barrett’s esophagus, being predictor variable. performed chi-square test, descriptive analysis, as well simple multiple logistic regressions assess associations. Results: 4,633,135 adults GERD. Approximately 0.16% patients had esophagitis, while 1.18% esophagus. Alcohol (2.04%), (1.96%), more than one-tenth cigarettes (12.21%). Majority population are female (57.56%), white (77.51%) ≥65 years (58.03%). users (aOR = 1.801 [1.389-2.335], P < .0001) likely have or esophagus (1.226 [1.054-1.426], 0.0081) compared non-users. Conclusion: associated Therefore, we recommend educating on making healthy lifestyle choices, such abstaining from moderating substances like marijuana. Additional studies required define safe amounts recreational

Language: Английский

Citations

0
Facile fabrication of the immuno-MALDI-MS chip for the enrichment of abused drug in human urine integrated with MALDI-MS analysis DOI

Hsin-Ping Chen,

He‐Hsuan Hsiao

Analytica Chimica Acta, Journal Year: 2024, Volume and Issue: 1329, P. 343224 - 343224

Published: Sept. 11, 2024

Language: Английский

Citations

1
Cannabis for medicine and food: A benefit vs risk critical appraisal DOI Creative Commons
Murendeni Nethengwe,

Y Maphosa,

BO Ahiante

et al.

South African Journal of Botany, Journal Year: 2024, Volume and Issue: 175, P. 15 - 31

Published: Oct. 11, 2024

Language: Английский

Citations

1
Endogenous Cannabinoids in Crohn’s Disease DOI Creative Commons

Michał S. Bochenek,

J. Tomášík, Andrzej Wędrychowicz

et al.

Applied Sciences, Journal Year: 2024, Volume and Issue: 14(15), P. 6646 - 6646

Published: July 30, 2024

Background: An increasing number of people around the world suffer from Crohn’s disease (CD), one inflammatory bowel diseases (IBDs). Recent evidence suggests that endogenous cannabinoid system plays an important role in IBD. The main endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), are ligands CB1 CB2 receptors expressed on immune cells. These as well endocannabinoids believed to mediate activity participate pathophysiology CD. Objective: Very little is known about secretion cannabinoids throughout course Therefore, aim this study was determine analyze 2-AG AEA concentrations children who suffered Methods: We studied 34 adolescents with CD, mean age 13.5 years ± 2.0. Blood samples were collected three times active phase (during admission hospital, before treatment), 2–4 weeks later, during treatment clinical improvement patients, 3–6 months period remission. control group included 33 healthy teenagers same examined once. In all fasting blood morning. 2AG serum measured using EIA kits (Abclonal, Woburn, MA, USA ELK Biotechnology Co., Ltd. Wuhan, China, respectively). Results: median concentration stable: acute 907.4 [379.3; 1300.5] pg/mL, 715.1 [416.7; 1302.5] pg/mL; remission 991.1 [381.1; 1652.5] similar values observed 761.8 [504.3; 1497.0] pg/mL. No significant differences found between results obtained at time points compared (in cases p > 0.44). case AEA, treatment, 2.63 [2.24; 2.79] ng/mL 2.56 [2.33; 3.06] ng/mL, remission, 2.61 [2.46; 2.85] ng/mL. All these lower 3.18 [2.57; 3.88] (p = 0.023, 0.035, 0.056, Conclusions: While levels remained stable comparable controls, consistently CD patients. therapeutic interventions aimed AEA-related signaling, such administration its analogues or fatty acid amide hydrolase inhibitors, may improve symptoms associated children.

Language: Английский

Citations

0